natgillin/translations-raw huggingface dataset:
You should specifically tell your doctor if you take - medicines that may increase your risk of bleeding such as: o oral anticoagulants, medicines used to reduce blood clotting, o a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints, o heparin or any other injectable medicine used to reduce blood clotting, o ticlopidine, other antiplatelet agent, o a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression, - omeprazole or esomeprazole, medicines to treat upset stomach, - fluconazole or voriconazole, medicines to treat fungal infections, - efavirenz, a medicine to treat HIV (human immunodeficiency virus) infections, 
Še posebej pomembno je, da obvestite svojega zdravnika, če jemljete - zdravila, ki lahko povečajo tveganje za krvavitve, kot so: o peroralni antikoagulanti, zdravila, ki preprečujejo nastanek krvnih strdkov, o nesteroidna protivnetna zdravila, ki se običajno uporabljajo za lajšanje bolečine in/ali vnetja mišic ali sklepov, o heparin, ali katerokoli drugo zdravilo v obliki injekcij, ki se uporablja za zmanjševanje strjevanja krvi, o tiklopidin, druga antiagregacijska zdravila, o selektivni zaviralci privzema serotonina (vključno a ne omejeno na fluoksetin ali fluvoksamin), zdravila, ki se običajno uporabljajo za zdravljenje depresije, - omeprazol ali esomeprazol, zdravila za zdravljenje težav z želodcem, - flukonazol ali vorikonazol, zdravila za zdravljenje glivičnih okužb,
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Krka (4 tablets of 75 mg) once at the start of treatment. 
Če ste imeli hudo bolečino v prsih (nestabilna angina pektoris ali srčna kap), vam lahko zdravnik na začetku zdravljenja da enkrat 300 mg zdravila Klopidogrel Krka (štiri 75-mg tablete).
In patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). 
Pri bolnikih z akutnim koronarnim sindromom: - Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca):zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).
How to take Clopidogrel Krka 
Kako jemati zdravilo Klopidogrel Krka
Name and address of the manufacturer(s) responsible for batch release 
PROIZVAJALEC (PROIZVAJALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
Do not stop the treatment unless your doctor tells you so. 
Če ste prenehali jemati zdravilo Klopidogrel Krka Ne prekinite zdravljenja razen, če tako odloči zdravnik.
- ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300 mg loading dose in combination with ASA and with or without thrombolytics. 
- Akutni miokardni infarkt z elevacijo ST spojnice: klopidogrel je potrebno dajati v enkratnem dnevnem odmerku 75 mg, zdravljenje pa je potrebno začeti s 300 mg udarnim odmerkom v kombinaciji z ASA ter z/brez uporabe trombolitikov.
How to take Clopidogrel Krka 4. 
Shranjevanje zdravila Klopidogrel Krka 6.
Clopidogrel Krka 75 mg film-coated tablets 
Klopidogrel Krka 75 mg filmsko obložene tablete
Clopidogrel Krka contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. 
Zdravilo Klopidogrel Krka vsebuje klopidogrel in spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
Clopidogrel Krka 75 mg film-coated tablets clopidogrel 
Klopidogrel Krka 75 mg filmsko obložene tablete klopidogrel
- Severe hepatic impairment. 
- Huda jetrna okvara.
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1752) or placebo (n=1739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin. 
Bolniki so dobivali klopidogrel (300 mg udarni odmerek, nato pa 75 mg na dan, n=1.752) ali placebo (n=1.739), oboje v kombinaciji z ASA (150 mg do 325 mg kot udarni odmerek, nato 75 mg do 162 mg na dan), fibrinolitičnim sredstvom in po potrebi heparinom.
Combined therapy should be started as early as possible after symptoms start and continued for at least four weeks The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1). 
S kombiniranim zdravljenjem je potrebno začeti čim prej po nastopu simptomov in z njim nadaljevati vsaj štiri tedne.
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Krka. 
Iz varnostnih razlogov naj matere, ki se zdravijo z zdravilom Klopidogrel Krka, ne dojijo.
77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day). 
O kancerogenem učinku klopidogrela v odmerkih do 77 mg/kg na dan (kar predstavlja najmanj 25-krat večjo izpostavljenost kot pri človeku ob jemanju kliničnega odmerka 75 mg na dan), ki so ga mišim dajali 78 tednov, podganam pa 104 tedne, ni bilo dokazov.
Gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia 
motnje okusa, agevzija glavobol, parestezije, omotica
In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the placebo plus ASA group.The incidence of major bleeding was similar between groups. 
V študiji CLARITY je v skupini s klopidogrelom in ASA prišlo do splošnega povečanja krvavitev v primerjavi s skupino s placebom in ASA.
If you forget to take a dose of Clopidogrel Krka, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time. 
Če ste pozabili vzeti odmerek in od tega ni minilo več kot 12 ur, ga vzemite takoj, ko se spomnite.
Clopidogrel Krka is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Proces je znan kot aterotromboza in lahko povzroči aterotrombotične dogodke (kot so kap, srčni napad ali smrt).
Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness 
Bolezni živčevja intrakranialna krvavitev (opisani so primeri s smrtnim izidom),
The most common side effect is bleeding. 
Najpogostejši neželeni učinek, o katerem so poročali med zdravljenjem z zdravilom Klopidogrel Krka, je krvavitev.
It can be used in the following groups of patients who have a condition known as ‘acute coronary syndrome': 
Uporablja se lahko pri naslednjih skupinah bolnikov, ki imajo bolezen, imenovano „akutni koronarni sindrom“:
The Committee also considered that combining both active substances in a single tablet simplifies treatment for patients as they will need to take fewer tablets. 
Prav tako je menil, da bo kombinacija obeh zdravilnih učinkovin v eni tableti poenostavila zdravljenje za bolnike, saj bodo morali jemati manj tablet.
• patients being treated for heart attack with ST-segment elevation, when the doctor thinks that they would benefit from treatment to dissolve blood clots. 
• pri bolnikih, ki se zdravijo zaradi srčne kapi z elevacijo ST-spojnice, kadar zdravnik meni, da bi jim zdravljenje koristilo za raztopitev krvnih strdkov.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Clopidogrel/Acetylsalicylic acid Teva's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Klopidogrel/acetilsalicilna kislina Teva večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The full EPAR and risk management plan summary for Clopidogrel/Acetylsalicylic acid Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Klopidogrel/acetilsalicilna kislina Teva sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This means that they help to prevent blood cells called platelets from sticking together and forming clots, thus helping to prevent another heart attack. 
To pomeni, da pomagata preprečiti, da bi se krvne celice, imenovane trombociti, sprijele in tvorile strdke, kar pomaga preprečiti novo srčno kap.
The European Commission granted a marketing authorisation valid throughout the European Union for Clopidogrel/Acetylsalicylic acid Teva on 01 September 2014. 
Evropska komisija je dovoljenje za promet z zdravilom Klopidogrel/acetilsalicilna kislina Teva, veljavno po vsej Evropski uniji, izdala 1. septembra 2014.
Clopidogrel/Acetylsalicylic acid Teva must not be used during the last three months of pregnancy. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva se ne sme uporabljati v zadnjem trimesečju nosečnosti.
It also presented the results of 3 previous studies involving in total over 61,000 patients with unstable angina or who had had a heart attack, which showed that the combination of clopidogrel and acetylsalicylic acid taken as separate tablets was more effective at preventing events such as heart attacks than acetylsalicylic acid alone. 
Prav tako je predložila rezultate treh predhodnih študij, v katerih je sodelovalo skupno več kot 61 000 bolnikov, ki so imeli nestabilno angino pektoris ali so doživeli srčno kap, in v katerih so ugotovili, da je bila kombinacija klopidogrela in acetilsalicilne kisline v ločenih tabletah učinkovitejša od same acetilsalicilne kisline pri preprečevanju dogodkov, kot so srčne kapi.
Clopidogrel has been authorised since 1998 for reducing platelet aggregation, and is often used in combination with acetylsalicylic acid. 
Klopidogrel je za zmanjševanje agregacije trombocitov odobren od leta 1998 in se pogosto uporablja v kombinaciji z acetilsalicilno kislino.
The combination of the two active substances has an additive effect, reducing the risk of blood clots forming more than either medicine alone. 
Kombinacija teh dveh zdravilnih učinkovin ima aditiven učinek, tako da zmanjša tveganje za nastanek krvnih strdkov bolj kot katero koli od teh zdravil posamično.
This is a summary of the European public assessment report (EPAR) for Clopidogrel/Acetylsalicylic acid Teva. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Klopidogrel/acetilsalicilna kislina Teva.
Because the two active substances have been used together for a number of years, the company presented the results of studies showing that the active substances in Clopidogrel/Acetylsalicylic acid Teva are absorbed in the body in the same way when taken in a single tablet as when the two medicines are taken separately. 
Ker se zdravilni učinkovini uporabljata skupaj že vrsto let, je družba predložila rezultate študij, ki so pokazale, da se zdravilni učinkovini v zdravilu Klopidogrel/acetilsalicilna kislina Teva v telesu absorbirata enako, kadar se vzameta v eni tableti in kadar se vzameta ločeno.
It is used to prevent problems caused by blood clots, such as a heart attack, in adults who are already taking both clopidogrel and acetylsalicylic acid (known commonly as aspirin) as separate tablets. 
Uporablja se za preprečevanje težav zaradi krvnih strdkov, kot je na primer srčna kap, pri odraslih, ki že jemljejo klopidogrel in acetilsalicilno kislino (splošno znano kot aspirin) v ločenih tabletah.
The CHMP noted that both active substances in Clopidogrel/Acetylsalicylic acid Teva have been used for several years to reduce the risk of heart attack and when taken together they can reduce the risk more than each component can alone. 
Odbor CHMP je upošteval, da se obe zdravilni učinkovini v zdravilu Klopidogrel/acetilsalicilna kislina Teva že vrsto let uporabljata za zmanjšanje tveganja za srčno kap in da lahko skupaj zmanjšata tveganje v večji meri kot vsaka učinkovina posebej.
Clopidogrel stops the platelets sticking together by blocking a substance called ADP from attaching to a special receptor on their surface. 
Klopidogrel prepreči sprijetje trombocitov tako, da prepreči, da bi se snov, imenovana ADP, vezala na poseben receptor na njihovi površini.
• patients who have unstable angina (a severe type of chest pain) or have had a heart attack with no ‘ST-segment elevation' (an abnormal reading on the ECG or electrocardiogram), including those who are having a stent (a short tube) inserted into an artery to prevent it from closing up; 
• pri bolnikih, ki imajo nestabilno angino pektoris (hudo obliko bolečine v prsih) ali so doživeli srčno kap brez „elevacije ST-spojnice“ (nenormalen izpis na EKG ali elektrokardiogramu), vključno s tistimi, ki imajo v arteriji vstavljen stent (kratko cevko), ki preprečuje, da bi se arterija zaprla;
It must not be used in patients who have a disease that is causing bleeding, such as stomach ulcer or bleeding in the brain, or in patients with mastocytosis (high blood levels of certain white blood cells called mast cells). 
Prav tako se ne sme uporabljati pri bolnikih, ki imajo bolezen, ki povzroča krvavitve, kot je na primer razjeda želodca ali krvavitev v možganih, in pri bolnikih z mastocitozo (visokimi ravnmi določenih belih krvnih celic, imenovanih mastociti, v krvi).
Clopidogrel/Acetylsalicylic acid Teva is available as tablets containing 75 mg clopidogrel, either with 75 mg or 100 mg acetylsalicylic acid. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva je na voljo v obliki tablet, ki vsebujejo 75 mg klopidogrela v kombinaciji z bodisi 75 mg ali 100 mg acetilsalicilne kisline.
The most common side effects with Clopidogrel/Acetylsalicylic acid Teva (which may affect up to 1 in 10 people) are haematoma (a collection of blood under the skin), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), diarrhoea, abdominal pain (stomach ache), dyspepsia (heartburn), bruising, and bleeding where the skin is punctured. 
Najpogostejši neželeni učinki zdravila Klopidogrel/acetilsalicilna kislina Teva (ki lahko prizadenejo največ 1 osebo od 10) so hematom (nabiranje krvi pod kožo), epistaksa (krvavitve iz nosu), gastrointestinalna krvavitev (krvavitev v želodcu ali črevesju), driska, bolečina v trebuhu (bolečina v želodcu), dispepsija (zgaga), podplutbe in krvavitev na mestu predrtja kože.
For more information about treatment with Clopidogrel/Acetylsalicylic acid Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Klopidogrel/acetilsalicilna kislina Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What measures are being taken to ensure the safe and effective use of Clopidogrel/Acetylsalicylic acid Teva? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Klopidogrel/acetilsalicilna kislina Teva?
Acetylsalicylic acid stops the platelets sticking together by blocking an enzyme called prostaglandin cyclo-oxygenase. 
Acetilsalicilna kislina prepreči sprijetje trombocitov tako, da zavira encim, imenovan prostaglandinska ciklooksigenaza.
The medicine is taken as a single tablet daily in place of the clopidogrel and acetylsalicylic acid tablets that the patient has already been taking separately. 
Zdravilo se jemlje z eno tableto na dan, ki jo bolnik vzame namesto tablet klopidogrela in acetilsalicilne kisline, ki ju je prej jemal ločeno.
Clopidogrel/Acetylsalicylic acid Teva must not be used in people who are hypersensitive (allergic) to clopidogrel, non-steroidal anti-inflammatory drugs (NSAIDs, used to relieve pain and inflammation) such as acetylsalicylic acid, or any of the other ingredients in Clopidogrel/Acetylsalicylic acid Teva. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva se ne sme uporabljati pri osebah, ki so preobčutljive za (alergične na) klopidogrel, nesteroidna protivnetna zdravila (NSAID, tj. zdravila, ki se uporabljajo za lajšanje bolečine in vnetja), kot je acetilsalicilna kislina, ali katero koli drugo sestavino zdravila Klopidogrel/acetilsalicilna kislina Teva.
This reduces the production of a substance called thromboxane, which normally helps clots to form by binding platelets together. 
Zaradi tega se zmanjša tvorba snovi, imenovane tromboksan, ki običajno veže trombocite skupaj in tako prispeva k nastanku strdkov.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Clopidogrel/Acetylsalicylic acid Teva, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Klopidogrel/acetilsalicilna kislina Teva in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
For practical information about using Clopidogrel/Acetylsalicylic acid Teva, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Klopidogrel/acetilsalicilna kislina Teva naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Both active substances in Clopidogrel/Acetylsalicylic acid Teva, clopidogrel and acetylsalicylic acid, are antiplatelet medicines. 
Obe zdravilni učinkovini v zdravilu Klopidogrel/acetilsalicilna kislina Teva, klopidogrel in acetilsalicilna kislina, sta antiagregacijski zdravili.
A risk management plan has been developed to ensure that Clopidogrel/Acetylsalicylic acid Teva is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Klopidogrel/acetilsalicilna kislina Teva je bil pripravljen načrt obvladovanja tveganj.
It must not be used in patients who have severely reduced liver or kidney function, or who have a medical condition that includes a combination of asthma, rhinitis (stuffy and runny nose) and nasal polyps (growths in the lining of the nose). 
Ne sme se uporabljati tudi pri bolnikih, ki imajo močno zmanjšano delovanje jeter ali ledvic ali obolenje, ki je kombinacija astme, rinitisa (zamašen nos in izcedek iz nosu) ter nosnih polipov (izrastki na nosni sluznici).
For the full list of all side effects reported with Clopidogrel/Acetylsalicylic acid Teva, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Klopidogrel/acetilsalicilna kislina Teva, glejte navodilo za uporabo.
Other information about Clopidogrel/Acetylsalicylic acid Teva 
Druge informacije o zdravilu Klopidogrel/acetilsalicilna kislina Teva
What are the risks associated with Clopidogrel/Acetylsalicylic acid Teva? 
Kakšna tveganja so povezana z zdravilom Klopidogrel/acetilsalicilna kislina Teva?
Clopidogrel/Acetylsalicylic acid Teva is a blood thinning medicine that contains two active substances, clopidogrel and acetylsalicylic acid. 
Klopidogrel/acetilsalicilna kislina Teva je zdravilo za redčenje krvi, ki vsebuje zdravilni učinkovini klopidogrel in acetilsalicilno kislino.
What is Clopidogrel/Acetylsalicylic acid Teva and what is it used for? 
Kaj je zdravilo Klopidogrel/acetilsalicilna kislina Teva in za kaj se uporablja?
What benefits of Clopidogrel/Acetylsalicylic acid Teva have been shown in studies? 
Kakšne koristi je zdravilo Klopidogrel/acetilsalicilna kislina Teva izkazalo v študijah?
Why is Clopidogrel/Acetylsalicylic acid Teva approved? 
Zakaj je bilo zdravilo Klopidogrel/acetilsalicilna kislina Teva odobreno?
Clopidogrel/Acetylsalicylic acid Teva clopidogrel / acetylsalicylic acid 
Klopidogrel/acetilsalicilna kislina Teva klopidogrel/acetilsalicilna kislina
Clopidogrel/Acetylsalicylic acid Teva can only be obtained with a prescription. 
Izdaja zdravila Klopidogrel/acetilsalicilna kislina Teva je le na recept.
How does Clopidogrel/Acetylsalicylic acid Teva work? 
Kako zdravilo Klopidogrel/acetilsalicilna kislina Teva deluje?
How is Clopidogrel/Acetylsalicylic acid Teva used? 
Kako se zdravilo Klopidogrel/acetilsalicilna kislina Teva uporablja?
This is called overgrowth. 
To se imenuje prekomerna rast.
if you are suffering from more than one infection. 
Če trpite zaradi več kot ene okužbe.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 02 September 2011 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 2. september 2011
From a microbiological point of view the product should be used immediately. 
Z mikrobiološkega stališča je treba zdravilo porabiti takoj.
A course of treatment usually lasts for 7 to 21 days. 
Zdravljenje običajno traja od 7 do 21 dni.
The minimum inhibitory concentration (MIC) breakpoints are as follows: 
Prekinitvene točke minimalne inhibitorne koncentracije (MIC) so naslednje:
Both effects were reversible following an 8 week recovery period. 
Oba učinka sta bila odpravljiva po 8-tedenskem obdobju okrevanja.
Stopping or slowing the infusion may result in cessation of these reactions. 
Zaustavitev ali upočasnitev infundiranja lahko ustavi te reakcije.
The potential risk for humans 
Potencialno tveganje za
At least 10,000 Gram-positive isolates per year shall be included in the study from the surveillance networks in Europe, USA, Latin America and Asia-Pacific. 
V študijo bo vključenih vsaj 10.000 grampozitivnih izolatov letno iz mrež namenskega spremljanja v Evropi, ZDA, Latinski Ameriki in Aziji s Tihim oceanom.
Intermediate analysis results should be provided starting May 2015. 
Rezultate vmesne analize je treba zagotavljati od maja 2015 naprej.
Telavancin has a small volume of distribution. 
Telavancin ima majhen volumen distribucije.
Final study results by 31 December 
Končni rezultati študije do 31. decembra
Consideration should be given to official guidance on the appropriate use of antibacterial agents. 
Razmisliti je treba o uradnih priporočilih glede ustrezne uporabe antibakterijskih učinkovin.
Alternatively, your doctor may decide that this medicine is not suitable for you. 
Namesto tega se lahko vaš zdravnik odloči, da to zdravilo za vas ni primerno.
The Healthcare Professional Guide should contain the following key messages: 
Priročnik za zdravstvene delavce mora vsebovati naslednja ključna sporočila:
The use of antibiotics may promote the overgrowth of non-susceptible micro-organisms. 
Uporaba antibiotikov lahko spodbudi prekomerno rast neobčutljivih mikroorganizmov.
Preparation of the reconstituted concentrate 
Priprava rekonstituiranega koncentrata
Tell your doctor that 
Povejte zdravniku,
Tell your doctor if you are pregnant, think you may be pregnant, or are trying to become pregnant. 
Povejte zdravniku, če ste noseči, sumite, da ste noseči ali poskušate zanositi.
if you are allergic to antibiotics such as vancomycin. 
Če ste alergični na antibiotike, kot je vankomicin.
What you need to know before you use VIBATIV 
Kaj morate vedeti, preden boste uporabili zdravilo VIBATIV
The first signs of a severe allergic reaction may include swelling of the skin, face and/or throat and/or difficulty breathing. 
Prvi znaki hude alergijske reakcije so lahko otekanje kože, obraza in/ali grla in/ali težko dihanje.
The elimination half-life in subjects with normal renal function is approximately 8 hours. 
Razpolovna doba izločanja pri osebah z običajno ledvično funkcijo je približno 8 ur.
Human plasma protein binding is approximately 90%, primarily to serum albumin. 
Vezava na humane plazemske proteine je približno 90 %, predvsem na serumski albumin.
Your doctor will treat you as necessary. 
Vaš zdravnik vas bo zdravil, kot je potrebno.